[Radioiodine therapy for benign thyroid diseases (version 5). German Guideline]

Nuklearmedizin. 2016 Dec 6;55(6):213-220. doi: 10.3413/Nukmed-0823-16-04.
[Article in German]

Abstract

The version 5 of the guideline for radioiodine therapy of benign thyroid disorders is an update of the version 4, which was published by the German Society of Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizin, DGN) in co-ordination with the German Society of Endocrinology (Deutsche Gesellschaft für Endokrinologie, DGE, Sektion Schilddrüse) and the German Society of General- and Visceral-Surgery (Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie, DGAV) in 2007. This guideline was harmonized with the recommendations of the European Association of Nuclear Medicine (EANM). According to the German "Directive on Radiation Protection in Medicine" the physician specialised in nuclear medicine ("Fachkunde in der Therapie mit offenen radioaktiven Stoffen") is responsible for the justfication to treat with radioiodine. Therefore, relevant medical indications for radioiodine therapy and alternative therapeutic options are discussed within the guideline. This procedure guideline is developed in the consensus of a representative expert group. This fulfils the level S1 (first step) within the German classification of Clinical Practice Guidelines.

Keywords: Graves’ disease; Guideline; hyperthyroidism; radioiodine therapy; thyrotoxicosis; toxic goiter.

MeSH terms

  • Evidence-Based Medicine
  • Germany
  • Humans
  • Hyperthyroidism / radiotherapy*
  • Iodine Radioisotopes / therapeutic use*
  • Nuclear Medicine / standards*
  • Practice Guidelines as Topic*
  • Radiopharmaceuticals / therapeutic use
  • Radiotherapy / standards*
  • Treatment Outcome

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals